Physician profile
Donna Catanzaro
NPI 1306838578
$1,010.43
in general payments reported to CMS, 2019-2025
12 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $205 · 2023: $155 · 2024: $385 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $407.33 | 2023-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $272.63 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $64.46 | 2020-2024 | Ozempic, Rybelsus |
| Angiodynamics, INC. | $54.73 | 2023-2025 | Bioflo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.15 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $31.94 | 2024-2025 | Zoryve |
| Pfizer INC. | $28.34 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.99 | 2025 | |
| Abbott Laboratories | $22.91 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $20.74 | 2024 | Lagevrio |
| Ani Pharmaceuticals, INC. | $20.14 | 2025 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $20.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Catanzaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.